JP4826995B2 - 抗体の変質を防止する精製方法 - Google Patents

抗体の変質を防止する精製方法 Download PDF

Info

Publication number
JP4826995B2
JP4826995B2 JP2005013897A JP2005013897A JP4826995B2 JP 4826995 B2 JP4826995 B2 JP 4826995B2 JP 2005013897 A JP2005013897 A JP 2005013897A JP 2005013897 A JP2005013897 A JP 2005013897A JP 4826995 B2 JP4826995 B2 JP 4826995B2
Authority
JP
Japan
Prior art keywords
antibody
arginine
protein
buffer
recovered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2005013897A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005206602A5 (OSRAM
JP2005206602A (ja
Inventor
良輔 弓岡
大輔 江島
力 荒川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34753090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4826995(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of JP2005206602A publication Critical patent/JP2005206602A/ja
Publication of JP2005206602A5 publication Critical patent/JP2005206602A5/ja
Application granted granted Critical
Publication of JP4826995B2 publication Critical patent/JP4826995B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
JP2005013897A 2004-01-21 2005-01-21 抗体の変質を防止する精製方法 Expired - Lifetime JP4826995B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53750304P 2004-01-21 2004-01-21
US60/537503 2004-01-21
US63140704P 2004-11-30 2004-11-30
US60/631407 2004-11-30

Publications (3)

Publication Number Publication Date
JP2005206602A JP2005206602A (ja) 2005-08-04
JP2005206602A5 JP2005206602A5 (OSRAM) 2008-03-06
JP4826995B2 true JP4826995B2 (ja) 2011-11-30

Family

ID=34753090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005013897A Expired - Lifetime JP4826995B2 (ja) 2004-01-21 2005-01-21 抗体の変質を防止する精製方法

Country Status (5)

Country Link
US (3) US8084032B2 (OSRAM)
EP (1) EP1568710B1 (OSRAM)
JP (1) JP4826995B2 (OSRAM)
CN (1) CN1680426B (OSRAM)
DE (1) DE602005018406D1 (OSRAM)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
EP1698637B1 (en) * 2005-03-03 2008-10-15 Ajinomoto Co., Inc. A method for improving recovery yield in protein purification with gel filtration chromatography using arginine
ATE551433T1 (de) * 2005-05-06 2012-04-15 Gen Probe Inc Verfahren und produkte zum erfassen von nukleinsäurezielen
SG162834A1 (en) * 2006-07-14 2010-07-29 Genentech Inc Refolding of recombinant proteins
KR20090064377A (ko) 2006-09-08 2009-06-18 와이어쓰 친화성 크로마토그래피를 사용하는 단백질 정제에 있어서 아르기닌 세척
TWI548747B (zh) 2006-09-13 2016-09-11 艾伯維有限公司 細胞培養改良
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
US8853371B2 (en) 2006-10-19 2014-10-07 Janssen Biotech, Inc. Process for preparing unaggregated antibody Fc domains
JP5505853B2 (ja) * 2007-02-13 2014-05-28 味の素株式会社 微酸性アルギニンを添加剤とするウイルス不活化法
CN102089319B (zh) * 2008-05-08 2013-11-13 味之素株式会社 蛋白质的重折叠方法
JP4542172B2 (ja) * 2008-05-19 2010-09-08 日本電波工業株式会社 感知装置及び感知方法
SG2013061528A (en) * 2008-08-14 2015-03-30 Merck Sharp & Dohme Methods for purifying antibodies using protein a affinity chromatography
RU2551237C2 (ru) 2008-10-20 2015-05-20 Эббви Инк Инактивация вируса при очистке антител
RU2520838C2 (ru) 2008-10-20 2014-06-27 Эббви Инк Выделение и очистка антител с использованием аффинной хроматографии на основе белка а
JP2011041475A (ja) * 2009-08-19 2011-03-03 Asahi Kasei Medical Co Ltd 抗体製造方法
PT2513134T (pt) 2009-12-18 2017-12-14 Novartis Ag Solução de lavagem e método para cromatografia de afinidade
KR101753569B1 (ko) * 2010-01-22 2017-07-04 베링거 인겔하임 인터내셔날 게엠베하 Ｆｃ―함유 단백질을 정제하는 크로마토그래피 방법
ES2544284T3 (es) 2010-02-26 2015-08-28 Ajinomoto Co., Inc. Composición que inactiva virus que contiene un compuesto de bajo peso molecular y arginina
WO2011162210A1 (ja) * 2010-06-21 2011-12-29 協和発酵キリン株式会社 アミノ酸を利用したタンパク質の精製方法
PT2714714T (pt) * 2011-06-01 2018-10-22 Novartis Ag Solução de lavagem e método para cromatografia de afinidade
CN103608463A (zh) 2011-06-23 2014-02-26 味之素株式会社 由使具有免疫球蛋白折叠结构的蛋白和能够形成亚单元结构的蛋白融合而得到的单体蛋白组成的多聚体蛋白的制备方法
US20150239956A1 (en) * 2012-06-27 2015-08-27 Asahi Kasei Medical Co., Ltd. High-affinity antibody and method for manufacturing the same
US9976163B2 (en) 2012-10-03 2018-05-22 Kyowa Hakko Kirin Co., Ltd Method for preventing reduction of polypeptide by adding amino acid to culture solution
RS57864B1 (sr) 2013-06-17 2018-12-31 De Staat Der Nederlanden Vert Door De Minister Van Vws Ministerie Van Volksgezondheid Welzijn En Spo Postupci za sprečavanje agregacije virusnih komponenti
JP6236948B2 (ja) * 2013-07-17 2017-11-29 東ソー株式会社 抗体精製用溶出液および当該溶出液を用いた抗体精製方法
CN105273041A (zh) * 2014-07-08 2016-01-27 上海中信国健药业股份有限公司 一种蛋白质亲和层析洗脱方法
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
CA2964786C (en) * 2014-10-23 2023-10-17 Amgen Inc. Reducing the viscosity of pharmaceutical formulations with n-acetyl amino acids
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
EP3374371A4 (en) * 2015-11-09 2019-12-11 University of Notre Dame SMALL MOLECULE AFFINITY MEMBRANE PURIFICATION SYSTEMS AND USE THEREOF
HRP20160086A2 (hr) 2016-01-27 2017-08-11 Sveučilište u Zagrebu Eluens za imunoafinitetnu kromatografiju virusa i proteina
US11186858B1 (en) 2016-03-15 2021-11-30 Fresenius Kabi Deutschland Gmbh Methods for increasing biosimilarity
US11708390B2 (en) 2016-05-11 2023-07-25 Cytiva Bioprocess R&D Ab Method of storing a separation matrix
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
EP3455243B1 (en) 2016-05-11 2021-03-24 Cytiva BioProcess R&D AB Separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US11753438B2 (en) 2016-05-11 2023-09-12 Cytiva Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
ES2994244T3 (en) 2016-07-25 2025-01-21 Cephalon Llc Affinity chromatography wash buffer
IL309453A (en) 2016-08-16 2024-02-01 Regeneron Pharma A method for quantifying individual antibodies from a mixture
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
IL289895B (en) 2016-10-25 2022-09-01 Regeneron Pharma Methods and systems for analysis of chromatography data
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
JP6897761B2 (ja) * 2017-04-07 2021-07-07 コニカミノルタ株式会社 タンパク質修飾蛍光体集積粒子の精製物を製造する方法、蛍光染色液の製造方法、タンパク質修飾蛍光体集積粒子の精製物、蛍光染色液およびタンパク質修飾蛍光体集積粒子精製用フィルター
CA3073935A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals, Inc. Methods of reducing particle formation and compositions formed thereby
JP7158015B2 (ja) * 2017-11-09 2022-10-21 国立研究開発法人産業技術総合研究所 ポリペプチドの凝集化抑制方法
CN111902720B (zh) 2018-03-21 2025-02-07 沃特世科技公司 基于非抗体高亲和力的样品制备、吸附剂、装置和方法
TW202448568A (zh) 2018-07-02 2024-12-16 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
KR20220039744A (ko) 2019-08-02 2022-03-29 유씨비 바이오파마 에스알엘 항체 정제 방법
KR20220078634A (ko) * 2019-10-04 2022-06-10 메르크 파텐트 게엠베하 단백질 a 친화성 크로마토그래피에서 모노클로날 항체의 용리
CN112898413A (zh) * 2021-04-07 2021-06-04 杭州奕安济世生物药业有限公司 采用亲和层析纯化减少抗体聚集的方法
CN113980092B (zh) * 2021-12-09 2024-05-14 上海药明生物技术有限公司 一种蛋白质亲和纯化方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1323567C (en) 1987-10-05 1993-10-26 Gene R. Nathans Method for purification of antibodies
JPH02273194A (ja) 1989-04-14 1990-11-07 Sumitomo Chem Co Ltd ヒトモノクローナル抗体の安定な精製法
AU5292693A (en) 1992-10-02 1994-04-26 General Hospital Corporation, The Affinity purification methods involving amino acid mimetics as elution reagents
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7223848B2 (en) 2001-06-05 2007-05-29 Genetics Institute, Llc Methods for purifying Fc-containing proteins
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
EP1698637B1 (en) 2005-03-03 2008-10-15 Ajinomoto Co., Inc. A method for improving recovery yield in protein purification with gel filtration chromatography using arginine
JP5505853B2 (ja) 2007-02-13 2014-05-28 味の素株式会社 微酸性アルギニンを添加剤とするウイルス不活化法
CN102089319B (zh) 2008-05-08 2013-11-13 味之素株式会社 蛋白质的重折叠方法

Also Published As

Publication number Publication date
US20120264918A1 (en) 2012-10-18
CN1680426B (zh) 2010-05-26
EP1568710A3 (en) 2005-10-05
EP1568710B1 (en) 2009-12-23
US8084032B2 (en) 2011-12-27
US20050176109A1 (en) 2005-08-11
CN1680426A (zh) 2005-10-12
US20120142901A1 (en) 2012-06-07
US8435527B2 (en) 2013-05-07
JP2005206602A (ja) 2005-08-04
DE602005018406D1 (de) 2010-02-04
EP1568710A2 (en) 2005-08-31
US8470328B2 (en) 2013-06-25

Similar Documents

Publication Publication Date Title
JP4826995B2 (ja) 抗体の変質を防止する精製方法
ES2688348T3 (es) Solución y método de lavado para cromatografía de afinidad
ES2651065T3 (es) Solución de lavado y método para cromatografía de afinidad
CN102712673B (zh) 用于纯化含fc的蛋白的色谱方法
US20120141497A1 (en) Methods of purifying small modular immunopharmaceutical proteins
RU2759909C2 (ru) Способы очистки антител
CN105008384A (zh) 在高电导率下在非离子性有机聚合物的存在下的蛋白质纯化
CN106164086A (zh) 抗体纯化方法
WO2020045477A1 (ja) ポリペプチドの精製方法
Chollangi et al. ted
HK1176946A1 (zh) 纯化免疫球蛋白溶液的方法
HK1176946B (en) Method for purifying immunoglobulin solutions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110822

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140922

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4826995

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110904

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140922

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term